Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostication refinement in NPM1-mutated acute myeloid leukemia stratified by FLT3-ITD status with different induction doses of cytarabine.

Cancer medicine - 1 Apr 2023

Wang Biao, Hua Xiaoying, Zhang Jihong, Gu Weiying, Li Haiqian

Abstract excerpt

OBJECTIVE: We aimed to retrospectively discern the heterogeneity of outcomes from clinicopathological characteristics and next-generation sequencing (NGS) data in adult patients with NPM1-mutated (NPM1mut ) acute myeloid leukemia (AML) induced with standard-dose (SD, 100-200 mg/m2 ) and intermediate-dose (ID, 1000-2000 mg/m2 ) cytarabine arabinose (Ara-C). METHODS: In the entire cohort and FLT3-ITD subgroups,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytarabine
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Nuclear Proteins

Share to Nucleophosmin

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 36808479
DOI: 10.1002/cam4.5704
PMCID: PMC10166952

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostication refinement in NPM1-mutated acute myeloid leukemia stratified by FLT3-ITD status with different induction doses of cytarabine.PMID 36808479Read ↗

Prognostic Relevance of NPM1 and FLT3 Mutations in Acute Myeloid Leukaemia, Longterm Follow-Up—A Single Center ExperienceSemantic proximity Read ↗

Mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia.Semantic proximity Read ↗

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.Semantic proximity Read ↗

The characteristics and prognostic analysis of therapy-related acute myeloid leukemia patients in China.Semantic proximity Read ↗

Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?Semantic proximity Read ↗

Cytogenetic and Molecular Genetic Driven Prediction of Response to First-Treatment and Prognosis in Acute Myeloid Leukemia: A Retrospective Cohort Study.Semantic proximity Read ↗

Prognostic impact of clinico-genetic characteristics and donor types in NPM1-mutated AML undergoing allogeneic hematopoietic stem cell transplantation.Semantic proximity Read ↗

Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.Semantic proximity Read ↗

A novel hierarchical prognostic model of AML solely based on molecular mutations.Semantic proximity Read ↗

Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

The correlation of next-generation sequencing-based genotypic profiles with clinicopathologic characteristics in NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.